Schroder Investment Management Group lowered its stake in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,768,941 shares of the company's stock after selling 154,726 shares during the period. Schroder Investment Management Group owned approximately 1.59% of HUTCHMED worth $39,762,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Public Employees Retirement System of Ohio purchased a new position in shares of HUTCHMED in the third quarter worth approximately $35,000. Blue Trust Inc. grew its position in HUTCHMED by 99.9% during the 4th quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after purchasing an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC raised its stake in HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after purchasing an additional 1,647 shares during the period. Crossmark Global Holdings Inc. lifted its holdings in shares of HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after purchasing an additional 1,799 shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of HUTCHMED in the third quarter worth $421,000. Institutional investors own 8.82% of the company's stock.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
Read Our Latest Stock Report on HUTCHMED
HUTCHMED Trading Down 5.7 %
NASDAQ HCM traded down $0.87 during trading on Friday, reaching $14.38. The company's stock had a trading volume of 110,830 shares, compared to its average volume of 107,412. The business has a 50-day moving average price of $14.90 and a 200-day moving average price of $16.37. HUTCHMED has a 1-year low of $12.84 and a 1-year high of $21.92. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
About HUTCHMED
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
